ABSTRACT
OBJECTIVES: To assess the outcome of population-based newborn screening for mucopolysaccharidosis type II (MPS II) during the first year of screening in Illinois. STUDY DESIGN: Tandem mass spectrometry was used to measure iduronate-2-sulfatase (I2S) activity in dried blood spot specimens obtained from 162 000 infant samples sent to the Newborn Screening Laboratory of the Illinois Department of Public Health in Chicago. RESULTS: One case of MPS II and 14 infants with pseudodeficiency for I2S were identified. CONCLUSIONS: Newborn screening for MPS II by measurement of I2S enzyme activity was successfully integrated into the statewide newborn screening program in Illinois.
Subject(s)
Iduronic Acid/analogs & derivatives , Mucopolysaccharidosis II/diagnosis , Neonatal Screening/methods , Biomarkers/blood , Dried Blood Spot Testing/methods , Follow-Up Studies , Humans , Iduronic Acid/blood , Illinois/epidemiology , Incidence , Infant, Newborn , Mucopolysaccharidosis II/blood , Mucopolysaccharidosis II/epidemiology , Reproducibility of Results , Retrospective Studies , Tandem Mass Spectrometry/methods , Time FactorsABSTRACT
Sodium reduction strategies on a population-based level are promoted as a public health intervention. Small and rural hospitals in Illinois were funded to adopt sodium reduction strategies as an intervention, have their hospital cafeteria and vending machines assessed via an environmental scan, and participate in an evaluation. Intervention strategies to identify and to label lower-sodium foods were implemented most, and pricing strategies were implemented least among funded hospitals. The sodium reduction strategies implemented could be replicated in other small and rural hospitals, because they were done with minimal funding and with minimal barriers.
